RPS6KA6 and acute myeloid leukemia: Given that previous studies have shown RSK4 to act as a tumor suppressor and also ERK/MPAK pathway exhibiting increased activity in AML, we analyzed RSK4 expression changes in blood and bone marrow samples of AML patients by quantitative teal-time polymerase change reaction (PCR).